Who are Ritlecitinib 20 mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-08052666, Pf-08046045, PF-06939999 in combination with docetaxel, Pf-07921585, Pf-07220060, Pf-07248144.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ritlecitinib-20-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ritlecitinib 20 mg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ritlecitinib 20 mg (ritlecitinib-20-mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: small molecule inhibitor. Area: Dermatology.

marketed small molecule inhibitor JAK3/STAT3 pathway Dermatology Live · refreshed every 30 min

Target snapshot

Ritlecitinib 20 mg (ritlecitinib-20-mg) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ritlecitinib 20 mg TARGET	ritlecitinib-20-mg	Pfizer	marketed	small molecule inhibitor	JAK3/STAT3 pathway
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown
Pf-08046045	pf-08046045	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	TBD
PF-06939999 in combination with docetaxel	pf-06939999-in-combination-with-docetaxel	Pfizer	marketed	Small molecule inhibitor	Specific protein kinase	Not yet determined
Pf-07921585	pf-07921585	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	Not available
Pf-07220060	pf-07220060	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Not available
Pf-07248144	pf-07248144	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Not available

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (small molecule inhibitor class)

Kalypsys, Inc. · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ritlecitinib 20 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ritlecitinib-20-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab